Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
Sanofi and Janssen join forces to develop E.coli vaccine, with Sanofi's $175M upfront payment
12:05pm, Tuesday, 03'rd Oct 2023
Sanofi revealed Tuesday that it had entered into an agreement with Janssen for the joint development and marketing of a vaccine candidate targeting extra-intestinal pathogenic E.coli.
FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE
09:46am, Tuesday, 26'th Sep 2023
If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in Jan
Sanofi: 3 Reasons For A Buy
09:26am, Thursday, 21'st Sep 2023
The French Pharma company is moving on an immunology franchise. Dupixent is the internal cash cow to drive lower debt and internal progress in the early-stage pipeline. Attractive valuation with a P/E
3 Stocks to Buy to Ride Europe's Coming Market Surge
03:04pm, Tuesday, 19'th Sep 2023
Are you looking for European stocks to buy? Bloomberg recently reported details about Bank of America's (NYSE: BAC ) latest survey of European fund managers.
First Wave BioPharma stock soars in active trading after Sanofi license deal
07:07am, Thursday, 14'th Sep 2023
Shares of First Wave BioPharma Inc. FWBI, +8.61% soared 71.7% in active premarket trading Thursday, after the biopharmaceutical company announced an agreement to license Capeserod to Sanofi SNY, -0.73
International Wide-Moat Stocks On Sale - The September 2023 Heat Map
09:05pm, Thursday, 07'th Sep 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of th
Why Sanofi (SNY) is a Top Dividend Stock for Your Portfolio
12:47pm, Thursday, 31'st Aug 2023
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?
Why Sanofi (SNY) is a Top Value Stock for the Long-Term
11:18am, Thursday, 31'st Aug 2023
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
2 Biotech Stocks That Could Make You Richer
10:00am, Friday, 18'th Aug 2023
Sanofi has a number of exciting growth drivers, some of which have earned approval relatively recently. Moderna shows it isn't just a pandemic stock as several non-COVID candidates inch toward approva
International Wide-Moat Stocks On Sale - The August 2023 Heat Map
12:36am, Wednesday, 09'th Aug 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of th
CDC panel says babies should get new drug that prevents RSV
06:35pm, Thursday, 03'rd Aug 2023
Infants should get a new drug to protect them against a respiratory virus that sends tens of thousands of American children to the hospital each year, heath advisers recommended Thursday.
US CDC approves Sanofi-AstraZeneca's preventive RSV therapy for babies
03:32pm, Thursday, 03'rd Aug 2023
The U.S. Centers for Disease Control and Prevention said on Thursday it had approved Sanofi and partner AstraZeneca's antibody therapy to prevent respiratory syncytial virus (RSV) in infants and toddl
The Top Healthcare Stocks to Buy With $100
07:45am, Sunday, 30'th Jul 2023
Medtronic's financial results should improve as the economy revives. Sanofi is making progress on several fronts, and there is more on the way.
Sanofi (SNY) Q2 2023 Earnings Call Transcript
02:23pm, Friday, 28'th Jul 2023
Sanofi (NASDAQ:SNY ) Q2 2023 Earnings Call Q2 2023 Earnings Call Transcript July 28, 2023 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head of Investor Relations Paul Hudson - Chief Executive
Sanofi (SNY) Beats on Q2 Earnings, Misses Sales, Stock Down
12:32pm, Friday, 28'th Jul 2023
Sanofi (SNY) beats second-quarter estimates for earnings but misses the same for sales. It raises the projected earnings growth range for 2023.
